1.. INTRODUCTION
================

Ceramides are the members of the sphingolipid family, which comprises fatty acids bound to sphingoid bases *via* amide bonds (Fig. **[1](#F1){ref-type="fig"}**) \[[@r1]\]. Ceramides are the major components in human skin, and account for approximately 50% of intercellular lipids in the stratum corneum. Although ceramides are lipids, they have hydrophilic groups that allow the formation of lamellar structures in the stratum corneum, in which water molecules are retained with ceramide, cholesterol and fatty acids. These structures play important roles in water-retention and the function of skin permeability barriers \[[@r2]-[@r4]\].

Previous studies of ceramide supplements in food and/or cosmetics have shown that ceramide contents decrease with age, leading to improved water retention and permeability barrier function \[[@r3]-[@r6]\]. In particular, plant-derived ceramides (glycosphingolipid) are characterized by glucosylceramide structures in which sugar moieties are bound to sphingolipids through β-bonds (Fig. **[2](#F2){ref-type="fig"}**) \[[@r7]\]. Sphingoid base and fatty acid compositions reportedly vary between plant species \[[@r8]\], and various ceramides are produced commercially from plants such as rice, corn, wheat and *Amorphophallus konjac* (konjac).

Because plants contain only trace amounts of ceramide, stable supply of plant-derived ceramides is hampered by large quantities of raw material and the requirement of advanced purification technologies, leading to high production costs. However, ceramide contents of peaches are greater than in other plants \[[@r7]\] and large peach-derived glucosylceramide yields have been achieved \[[@r9]\].

In this study, we investigated changes in ceramide contents following the treatment of three-dimensional human cultured skin with peach-derived glucosylceramide. We also assessed the effects of orally administered ceramide on skin functions, including water retention and permeability barrier functions, and demonstrated the safety of long-term supplementation with high doses of peach-derived ceramide.

2.. MATERIAL AND METHODS
========================

To investigate the clinical properties of peach-derived glucosylceramide, we determined **2.1**) ceramide contents in a human three-dimensional human cultured skin model, **2.2**) water retention and skin function effects following oral administration to humans, and **2.3**) long term safety of overdoses.

2.1.. Increases in Ceramide Contents in Three-dimensional Human Cultured Skin
-----------------------------------------------------------------------------

The effects of the peach-derived glucosylceramide on ceramide contents of skin were determined using the previously described methods \[[@r10]\].

### 2.1.1.. Materials

Purified peach-derived glucosylceramide was purchased from Okayasu Shoten Co., Ltd. (Koshigaya, Saitama, Japan). Three-dimensional human epidermal models, including Lab Cyte EPI-MODEL Air Lift 6 Days (12 well) and assay cultures for Lab Cyte were purchased from Japan Tissue Engineering Co., Ltd. (Gamagori, Aichi, Japan). Ceramide-2 and ceramide-5 were purchased from MATREYA LLC (Pleasant Gap, PA, USA), and ceramide-3 and ceramide-6 were purchased from Evonik (Goldschmidtstrabe, Essen, Germany). L-ascorbic acid, phosphate-magnesium salt n-hydrate, chloroform, methanol, and sodium benzoate were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Phosphate-buffered saline (PBS) tablets were purchased from Takara Bio Inc. (Otsu, Shiga, Japan). Sunsoft A-121 (penta-glycerol monolaurate) was purchased from Taiyo Kagaku Co., Ltd. (Tokyo, Japan), and sodium oleate was purchased from Junsei Chemical Co., Ltd. (Tokyo, Japan).

### 2.1.2.. Three-dimensional Cultures of Human Epidermal Skin Cells and Application of Peach-derived Glucosylceramide

Peach-derived glucosylceramide test solutions were prepared with 1% ceramide and were added to human epidermal cells in three-dimensional cultures. Test solutions were prepared by 1) sonicating solutions containing the purified peach-derived glucosylceramide, 0.2% Sunsoft A, 0.07% sodium benzoate, and purified water (-OA solution), or 2) 2% sodium oleate, 0.2% Sunsoft A, and 0.07% sodium benzoate (+OA solution) until constituents were evenly dissolved. PBS was used as a control solution, and 200-µL samples were applied to a Lab Cyte EPI-MODEL from the stratum corneum side and were incubated at 37°C in 5% CO~2~. Seven days later, culture media were replaced with fresh media containing L-ascorbic acid and phosphate-magnesium salt n-hydrate (25 µg/mL), and the cells were incubated for 24 h. Culture media were then replaced every day or every other day, and samples were applied every other day.

### 2.1.3.. Lipid Extraction from Three-dimensional Cultured Epidermis

After culture, cultured skin samples were carefully removed from scaffolds with the membrane filters of the cultivation cups in chloroform: methanol (2:1) using a surgical knife. Skin samples were then homogenized for 10 min using an Ultrasonic homogenizer (Advanced Sonifier 250; Branson Ultrasonics, Danbury, CT, USA) and lipids were extracted into the solution. Extraction solutions were then filtered through 0.2-µm filters (Millex-GN; Millipore, Billerica, Massachusetts, USA) using a glass syringe (VAN; TSUBASA INDUSTRY CO., LTD. Tokyo, Japan) and cellular debris was removed. Filtrates were exsiccated using a dry block bath (Dry Thermo Unit DTU-1C; Taitec, Koshigaya, Saitama, Japan), and lipid exsiccates were re-dissolved in 100 µL of chloroform:methanol (2:1).

### 2.1.4.. Quantification of Ceramide

Ceramide contents were determined in 10-µL sample aliquots after spotting onto a (HPTLC Silica Gel 60 F~254~; MERCK, Darmstadt, Hessen, Germany) using a glass capillary tube (Ringcaps; Hirschman Laborgerate, Eberstadt, Postfach, Germany). Identical volumes of ceramide-2 (NS), ceramide-3 (NP), ceramide-5 (AS), and ceramide-6 (AP) were spotted as standards, and spots were developed using a mixture of chloroform:methanol: acetic acid (190:9:1). Spots were developed upward to 1 cm from the top of the HPTLC plate and were then dried and developed again. After development, 8% aqueous phosphoric acid containing 10% copper sulfate was sprayed onto the plates and the plates were then incubated at 180°C for 10 min using TLC plate heater III (Camag, Sonnenmattstrasse, Muttenz, Switzerland). Resulting spots were imaged using a Luminoimage Analyzer System (LAS-1000 Plus; Fujifilm Corporation, Tokyo, Japan), and ceramide types and contents in resulting images were quantified using a Multi Gauge (Fujifilm Corporation, Tokyo, Japan).

### 2.1.5.. Data Analysis

Data are presented as mean ± standard deviations and were analyzed using Tukey's test with SAS 9.2 software (SAS Institute, Cary, NC, USA).

2.2.. Water Retention Effects of Orally Administered Peach Glucosylceramide
---------------------------------------------------------------------------

Skin water retention effects of peach-derived glucosylceramide were determined following oral administration to humans.

### 2.2.1.. Ethics

This study was conducted by Okayasu Shoten Co., Ltd.. The investigator explained the contents of the study, using the informed consent form to the subjects before conducting the study. Each subject who fully understood the contents of the study voluntarily participated in the study.

### 2.2.2.. Materials

Jelly containing 3% peach ceramide PF3 was purchased from Okayasu Shoten Co., Ltd. and was administered at 20 and 40 mg/day doses (peach-derived glucosylceramide at 0.6-and 1.2 mg/day). Control jelly was prepared without the peach ceramide PF3. Prior to preparation of jellies, all materials and peach ceramide were assessed using three-dimensional primary skin irritation experiments (in-house document) and reverse mutation tests in bacteria, and no safety issues were identified.

### 2.2.3.. Methods

#### 2.2.3.1.. Subjects and Methods of Administration

Twenty six healthy adult volunteers (13 males and 13 females; age, 27-67 years) agreed to get enrolled in this study after reading a study description (Table **[1.1](#T1.1){ref-type="table"}**). Subjects were assigned to groups with similar age and sex distributions (as much as possible). Subsequently, 3 subjects were included in the control group, 11 were treated with 20 mg/day PF3 (0.6 mg/day ceramide group), and 12 were treated with 40 mg/day PF3 (1.2 mg/day ceramide group; Table **[1.2](#T1.2){ref-type="table"}**). Jellies with and without ceramide were orally administered once daily with sufficient amounts of water within 30 min after breakfast.

#### 2.2.3.2.. Study Design

This open-label study was performed according to the schedule shown in Table **[2](#T2){ref-type="table"}**.

#### 2.2.3.3.. Duration of Study

Study materials were administered for 20 days from January 21 to February 9, 2015. During the study, subjects were instructed to live as they are accustomed and to avoid eating, drinking, and exercising excessively.

#### 2.2.3.4.. Study Items

Trans-Epidermal Water Loss (TEWL) was measured using a portable atomometer (VAPOMETER SWL4001JT; Delfin Technologies), and moisture contents of the stratum corneum at left brachial regions and left calves were measured using a Derma Unit SSC3/Corneometer CM825 (Integral Corporation) before the start of the study and at 10 and 20 days after the start of the study. Skin textures at left brachial regions were observed by taking pictures of epidermis using a USB digital microscope (DinoCapture2.0/DINOAM2001; Sanko Co., Ltd. × 200) two times before the study and 20 days after the start of the study.

#### 2.2.3.5.. Measurement Conditions

Subjects were to stay in a temperature-controlled room (22 ± 2°C at 40%RH) before examination to allow for acclimation.

#### 2.2.3.6.. Statistical Processing

TEWL and moisture volumes in the stratum corneum were expressed as percentages relative to initial values before administration (100%) and are presented as mean ± standard error. Differences between before and after treatments were identified using two-sided Dunnett's tests (t-test) and were considered significant when p \< 0.01 and p \< 0.05.

2.3.. Safety Evaluation of Long-term Treatments with Peach Ceramide
-------------------------------------------------------------------

The efficacy of peach-derived glucosylceramide was confirmed in clinical studies, as described in the previous section. Subsequently, long-term safety was determined using capsules containing approximately 18 mg of peach ceramide (glucosylceramide 5.4 mg; 4.5-9 times the recommended dose) and approximately 30% glucosylceramide. In this open label study, subjects of 20-65 years received capsules once daily for 12 weeks.

### 2.3.1.. Methods

#### 2.3.1.1.. Materials

Peach ceramide (30%) solutions were prepared from peach extracts containing peach-derived glucosylceramide (Okayasu Shoten). The ensuing glucosylceramide capsules contained γ-cyclodextrin and pig gelatin (Table **[3](#T3){ref-type="table"}**).

#### 2.3.1.2.. Subjects

Study candidates were required to answer preliminary questions, and those who met selection criteria A and did not meet exclusion criteria based on their answers passed the first selection. These candidates were screened and those who met selection criteria B were considered eligible. A total of 25 subjects were selected.

To ensure safety and protect human rights, subjects were informed of the study objectives in detail and provided written informed consent. The study was conducted in compliance with the ethical principles of the Declaration of Helsinki, and was approved by the Ethics Review Board at Shiba Palace Clinic (President: Motonori Sano, MD).

#### 2.3.1.3.. Selection Criteria A

1.  Japanese males and females of 20-60 years-of-age upon provision of consent.

2.  Healthy adults without serious organ damage or disease and who were not receiving related treatments or drug therapies.

#### 2.3.1.4.. Selection Criteria B

1.  Total cholesterol (T-Cho) level \< 260 mg/dL.

2.  Triglyceride (TG) level \< 350 mg/dL.

3.  Blood sugar (BS) level \< 120 mg/dL.

4.  γ-GT (γ-GTP) level \< 2 times the standard value.

5.  AST (GOT) level \< 2 times the standard value.

6.  ALT (GPT) level \< 2 times the standard value.

7.  Uric acid (UA) level \< 8.0 mg/dL.

8.  Creatinine (CRE) level \< 1.5 mg/dL.

9.  Systolic blood pressure between 101 mmHg and 139 mmHg.

10. Diastolic blood pressure between 61 mmHg and 89 mmHg.

#### 2.3.1.5.. Exclusion Criteria

1.  Subjects who were considered inappropriate for the study for various reasons as judged by the investigator.

2.  Subjects who were receiving a drug that might have affected the study results.

3.  Pregnant women, women who may have been pregnant, and women who were breastfeeding.

4.  Subjects who could have been allergic to the ingredients of the study products.

5.  Subjects who were participating in another clinical study.

6.  Subjects who had pre-existing conditions of serious hepatic impairment, renal impairment, or heart disease.

7.  Subjects who had pre-existing or current hepatitis.

8.  Subjects who had severe anemia.

9.  Subjects who were hypertensive.

10. T-Cho level ≥ 260 mg/dL.

11. TG level ≥ 350 mg/dL.

12. BS level ≥ 120 mg/dL.

13. γ-GTP level ≥ 2 times the standard value.

14. AST (GOT) level ≥ 2 times the standard value.

15. ALT (GPT) level ≥ 2 times the standard value.

16. UA level ≥ 8.0 mg/dL.

17. CRE level ≥ 1.5 mg/dL.

#### 2.3.1.6.. Study Design

This open-label study was conducted according to the schedule shown in Table **[4](#T4){ref-type="table"}**.

#### 2.3.1.7.. Study Duration

The study material was administered for 12 weeks from August 19 to November 11, 2015. During the study, subjects were instructed to live as they were accustomed and to avoid excessive eating, drinking, and exercising.

#### 2.3.1.8.. Method of Administration

Single capsules of the study material (Table **[3](#T3){ref-type="table"}**) were administered to subjects once daily after breakfast or supper with water or lukewarm water. When subjects skipped meals and suffered difficulty taking the capsule in the morning or evening, they were instructed to take predetermined doses anytime within that day.

#### 2.3.1.9.. Examination Items

##### 2.3.1.9.1.. Physical Examination (Body Weight)

Body weights were measured using a digital weight scale (WB-110; TANITA Corporation, Tokyo, Japan) at 0, 4, 8, and 12 weeks after the start of the administration period.

##### 2.3.1.9.2.. Laboratory Tests

Clinical laboratory tests were performed at 0, 4, 8, and 12 weeks after the start of the administration period.

Blood biochemical test included white blood cell counts, red blood cell counts, hemoglobin level, hematocrit, MCV, MCH, MCHC, platelet count, A/G ratio, total protein, albumin, UA, urea nitrogen, LDL cholesterol, CRE, sodium, potassium, chlorine, total cholesterol, TG, HDL cholesterol, total bilirubin, AST (GOT), ALT (GPT), ALP, γ-GT (γ-GTP), LD (LDH), and blood sugar levels.

Qualitative urinalyses comprised qualitative analyses of protein (score), sugar (score), urobilinogen (score), bilirubin (score), and ketone body (score) levels and occult blood reaction (score), specific gravity (numerical value), and reaction pH (numerical value) values.

Subjects fasted for 5 h before the tests (only water intake was allowed). All laboratory tests were performed at BML Inc. (Tokyo, Japan).

##### 2.3.1.9.3.. Blood Pressure (Seated Position) and Pulse Rate (Seated Position)

Blood pressures and pulse rate were measured five times in the seated position at the time of screening and at 0, 4, 8, and 12 weeks after the start of the administration period.

Blood pressures were measured after resting in the seated position for ≥ 10 min after arrival using an automated sphygmomanometer (HBP-9020; Omron Health Care Co., Ltd. Kyoto, Japan) and the second of two values were recorded and analyzed.

##### 2.3.1.9.4.. Investigation of Adverse Events

Adverse events were investigated in interviews of subjects on the basis of all unfavorable and unintended medical events, including signs, symptoms, and illnesses that took place between the start and end of the treatment period.

##### 2.3.1.9.5.. Statistical Processing

Continuous variables are expressed as mean ± standard deviations. Differences between blood pressure (seated position) and pulse rate (seated position), physical examination (body weight), blood biochemical test, and urinalysis (numerical value) results at the start and at 4, 8, and 12 weeks were identified using Dunnett's test. Urinalysis (score) results were analyzed using Wilcoxon signed-rank multiple comparison tests with Bonferroni's test for inequality. Two sided statistical analyses were performed using SPSS II for Windows (SPSS Co. Ltd.) and differences were considered significant when P \< 0.05.

3.. RESULTS
===========

3.1.. Increased in Ceramide Production
--------------------------------------

Peach-derived glucosylceramide (1%) was applied to three-dimensional human cultured skin models for 8 days, and ceramide was isolated and quantified using HPTLC (Fig. **[3](#F3){ref-type="fig"}** and **[4](#F4){ref-type="fig"}**). Treatment with peach-derived glucosylceramide tended to increase ceramide-2 (NS) contents, whereas ceramide-6 (AP) concentrations were significantly increased in the-OA group and ceramide-3 (NP), -5 (AS), and -6 (AP) contents were significantly increased in the +OA group. Total ceramide contents clearly increased following treatment with peach-derived glucosylceramide, and were particularly elevated in the +OA group.

3.2.. Water Retention Effects
-----------------------------

No subjects dropped out during the study and no particular abnormalities were observed following administration of the present treatments and controls.

### 3.2.1.. TEWL

Tendencies toward slight decreases in TEWL in brachial regions were observed in both 20- and 40-mg/day ceramide PF3 groups at 10 days after administration. After 20 days, TEWL were decreased by approximately 15% and 27% in 20- and 40-mg/day groups, respectively (Fig. **[5](#F5){ref-type="fig"}**). Similarly, TEWL decreased by 20%-30% in 20- and 40-mg/day groups at 10 days after treatment, and significant differences between these and baseline values were observed at 10 and 20 days (Fig. **[6](#F6){ref-type="fig"}**).

### 3.2.2.. Water Content in the Stratum Corneum

Water content of the stratum corneum tended to increase gradually in brachial regions of the 20-mg/day group, and were increased by 25% in the 40-mg/day group at 10 days and remained constant until the 20th day (Fig. **[7](#F7){ref-type="fig"}**). Water content of skin at calves in 20- and 40-mg/day PF3 treated subjects tended to increase by approximately 20% on the 10th day. On the 20th day, Water content were maintained in the 20-mg/day group but were increased by approximately 30% in the 40-mg/day group (Fig. **[8](#F8){ref-type="fig"}**).

### 3.2.3.. Skin Texture

Skin textures tended to improve in the 20-mg/day peach ceramide PF3 treated group (fine-textured skin; Fig. **[9](#F9){ref-type="fig"}**, middle). Similarly, 7 of 12 subjects in the 40-mg/day group showed improvements in skin texture. In particular, distinct cristae cutis and sulci cutis were observed in two subjects who showed substantial decreases in TEWL and had strong linear scars before administration. In these subjects, roughly textured skin became finely textured, indicating substantial improvements in skin conditions (Fig. **[9](#F9){ref-type="fig"}**, lower).

3.3.. Safety Evaluations
------------------------

Because no changes in the study protocol were made, the study was conducted according to the original schedule. No subjects dropped out or were excluded from the study and data analyses of all 25 subjects were performed according to details that were discussed at a clinical conference.

### 3.3.1.. Subjects

The mean age of the 25 subjects (14 males and 11 females) was 46.0 ± 8.8 years (males, 44.9 ± 8.7 years and females, 47.5 ± 9.1 years; Table **[5](#T5){ref-type="table"}**).

### 3.3.2.. Physical Examination

Body weights at the start of the treatment period and at 4, 8, and 12 weeks after the start are shown in Table **[6](#T6){ref-type="table"}**. Body weights did not differ between any of the time points.

### 3.3.3.. Laboratory Tests

The hematological and blood biochemical test results at the start of treatments and at 4, 8, and 12 weeks after the start are shown in Table **[7](#T7){ref-type="table"}**. However, significant differences in MCV, MCH, MCHC, TP, Alb, LDL cholesterol, creatinine, Cl, total cholesterol, HDL cholesterol, γ-GT (γ-GTP), and BS levels were identified between the start of the treatment period and at 4-, 8-, and 12-week follow-up examinations. No clinically problematic variations were observed in these values or in urinalysis (qualitative) results.

### 3.3.4.. Blood Pressure and Pulse Rates

Changes in blood pressures (seated position) and pulse rates (seated position) between the start of administration and 4, 8, and 12 weeks are shown in Table **[8](#T8){ref-type="table"}**. Although decreases in systolic and diastolic blood pressures were statistically significant, these were not sufficient to cause hypotension and were not clinically problematic.

### 3.3.5.. Adverse Events

No side effects were observed during the entire study period. However, 25 adverse events were recorded, and 10 of these (40%) were classified as cold (mild, non-serious), abdominal pain (mild, non-serious), diarrhea (mild, non-serious), abdominal bloating (mild, non-serious), constipation (mild, non-serious), pruritus (mild, non-serious), and insomnia (mild, non-serious). However, because all events were mild and were resolved within the study period, the study material was not considered a cause.

4.. DISCUSSION
==============

Human skin protects the body from physical impacts and prevents bacteria and viruses from entering the body. Skin has a three-layer structure comprising epidermis, dermis, and hypodermal fatty layer. The epidermis is approximately 0.2 mm thick, and includes the outermost layer of the skin and the stratum corneum, which provides a barrier and water retention functions to control the release of moisture from the body \[[@r1]\]. The structure of the stratum corneum comprises regularly aligned epidermal keratinocyte cells with lipid filled interstitial spaces. Although ceramide is the main interstitial lipid component \[[@r11]\], its contents decrease with aging \[[@r12], [@r13]\]. Accordingly, numerous studies of ceramide report efficacy and safety following addition to food and/or cosmetics, and application to skin restores water content and permeability functions \[[@r14]-[@r17]\].

In this study, we determined changes in ceramide contents following application of peach-derived glucosylceramide to three-dimensional human cultured skin. We confirmed that oral administration of peach-derived glucosylceramide facilitates water retention, and showed that long term administration of excessive glucosylceramide doses is safe in humans.

Treatments with peach-derived glucosylceramide dose dependently increased ceramide-2 (NS), -3 (NP), -5 (AS), and -6 (AP) levels in a three-dimensional human cultured skin model. Thus, transdermal application of the peach-derived glucosylceramide likely improves the water retention and barrier functions of skin. A previous study also showed that treatment of three-dimensional human cultured skin with rice-derived ceramide led to substantial increases in ceramide-5 (AS) levels, suggesting increased glucosylceramidase activity \[[@r10]\]. Although glycosphingolipid compositions of peach-derived glucosylceramide differ from those of rice-derived glucosylceramide, a similar mechanism of action is likely.

In the further experiments, oral administration of peach-derived glucosylceramide dose dependently decreased TEWL and increased water contents of the stratum corneum in human subjects. Furthermore, improvements in skin textures were observed, and these were substantial in subjects that had dry rough skin before taking the present peach derived ceramide tablets, indicating improved water retention and permeability barrier functions. In a previous study, rats were fed a corn-derived glucosylceramide, and following absorption through the digestive tract, glycosphingolipid, was used as a precursor to reconstitute skin ceramide levels \[[@r4], [@r18]\]. Hence, oral or transdermal administration of plant-derived ceramides, including those from rice, corn, and konjac, improved the water retention in skin \[[@r3], [@r14]-[@r16]\]. This study also confirmed the water retention effects of peach derived glucosylceramide, which has similar effects to those of other plant derived ceramides.

Peaches produce large amounts of ceramide \[[@r8]\] compared with other plants, and could be used as a stable and cost effective source of ceramide for cosmetics and supplements. Furthermore, the present open label trial in healthy 20-65 year-old Japanese subjects demonstrated the safety of long-term administration of peach ceramide. Our subjects consumed glucosylceramide capsules containing 4.5-9 times the recommended daily dose of 0.6-1.2 mg/day \[[@r3], [@r14], [@r19]\] for 12 weeks, and significant subjective or objective symptoms were observed. Moreover, although significant changes in physical examinations, hematological tests, and blood biochemical parameters were identified, these were all within normal physiological ranges.

Finally, mild reactions during glucosylceramide treatments were transient and were not specific to peach ceramide. Hence, these events were considered unrelated to the study material.

In conclusion, continuous daily administration of peach ceramide at high doses is safe and has beneficial effects on skin water retention and barrier function.

CONCLUSION
==========

When peach-derived glucosylceramide was applied to three-dimensional human cultured skin model, a dose-dependent increase in the human ceramide in the skin was observed. As a result of consecutive ingestion of 0.6 mg/day and 1.2 mg/day of glucosylceramide by 26 adults (average age, 47.9 years; 13 males and 13 females) for 20 consecutive days, improvement in skin water retention, suppression, and improvement in the texture of the skin *etc*. were observed. In addition, as a result of consecutive ingestion of 5.4 mg/day of glucosylceramide, which is equivalent to 4.5-9 times the recommended intake, by 25 adults (average age, 46.0 years; 14 males and 11 females), special physiological changes were not observed, and glucosylceramide was confirmed to be safe.
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###### 

Subjects.

  **Item**             **Total**     **Male**      **Female**
  -------------------- ------------- ------------- -------------
  Number of Subjects   26            13            13
  Age (Years)          47.9 ± 11.7   47.7 ± 12.3   48.0 ± 12.8

Mean ± standard deviation.

###### 

Allocations of subjects.

  **Item**              **Control**   **0.6 mg Arm**   **1.2 mg Arm**
  --------------------- ------------- ---------------- ----------------
  Numbers of Subjects   3             11               12
  Age (Years)           37.0 ± 5.4    51.5 ± 11.1      47.3 ± 13.4

Mean ± standard deviation.

###### 

Study schedule.

  **End Point**                **Before Administration**   **After 10-day Administration**   **After 20-day Administration**
  ---------------------------- --------------------------- --------------------------------- ---------------------------------
  Trans-epidermal water loss   〇                          〇                                〇
  Water content                〇                          〇                                〇
  Skin surface photograph      〇                          ―                                 〇
  Follow-up                                                                                  

###### 

Ingredients of peach extract capsules.

  **Ingredient**                                                                       **Content**
  ------------------------------------------------------------------------------------ -------------
  Peach ceramide (peach extract, peach-derived glucosylceramide-containing fraction)   18 mg
  γ-cyclodextrin                                                                       182 mg
  Hard capsule (pig gelatin)                                                           62 mg

###### 

Study schedule.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Endpoint**                       **Screening**   **Before**\            **4 Weeks after Administration**     **8 Weeks After Administration**     **12 Weeks after Administration**
                                                     **Administration**                                                                             
  -------------------------------- ----------------- -------------------- ------------------------------------ ------------------------------------ -------------------------------------
  Physical examination             \-                〇                   〇                                   〇                                   〇

  Clinical laboratory test         〇                〇                   〇                                   〇                                   〇

  Blood pressure/pulse             〇                〇                   〇                                   〇                                   〇

  Investigation of adverse event   \-                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Background of subjects.

  **Item**             **Total**    **Male**     **Female**
  -------------------- ------------ ------------ ------------
  Number of Subjects   25           14           11
  Age (Years)          46.0 ± 8.8   44.9 ± 8.7   47.5 ± 9.1

Mean ± standard deviation.

###### 

Physical examination (body weight).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Item**      **Unit**   **Before**\          **4 Weeks after Administration**   **Passage p-value from Start**   **8 Weeks after Administration**   **Passage p-value from Start**   **12 Weeks after Administration**   **Passage p-value from Start**
                           **Administration**                                                                                                                                                                               
  ------------- ---------- -------------------- ---------------------------------- -------------------------------- ---------------------------------- -------------------------------- ----------------------------------- --------------------------------
  Body Weight   kg         60.5 ± 12.8          60.6 ± 12.6                        P = 0.737                        60.5 ± 12.6                        P = 1.000                        60.5 ± 13.0                         P = 0.990

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mean ± standard deviations; n = 25.

###### 

Clinical laboratory test values.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Item**                         **Unit**     **Normal**       **Before Admin.**   **4 Weeks after**   **Overtime**\   **8 Weeks after**   **Overtime**\      **12 Weeks after**   **Overtime**\
                                                                                                         **P-Value**                         **p-Value**                             **p-Value**
  -------------------------------- ------------ ---------------- ------------------- ------------------- --------------- ------------------- ------------------ -------------------- ------------------
  White Blood Cell Count (WBC)     /μL          3500-9700        5177±1394           4902±1232           P = 0.465       4786±1219           P = 0.198          5279±1357            P = 0.940

  Red Blood Cell Count (RBC)       ×10^4^ μL    M: 438-577\      471±39              466±45              P = 0.524       465±39              P = 0.351          474±42               P = 0.728
                                                F: 376-516                                                                                                                           

  Hemoglobin (Hb)                  g/dL         M: 13.6-18.3\    14.1±1.4            14.1±1.7            P = 1.000       13.9±1.6            P = 0.381          14.1±1.7             P = 1.000
                                                F: 11.2-15.2                                                                                                                         

  Hematocrit (Ht)                  \%           M: 40.4-51.9\    42.3±3.6            42.0±4.2            P = 0.567       42.2±3.7            P = 0.963          42.4±4.1             P = 1.000
                                                F: 34.3-45.2                                                                                                                         

  MCV                              fL           M: 83-101\       90.1±4.5            90.2±4.4            P = 0.998       90.9±4.5            P = 0.033\*        89.3±4.3             P = 0.023\*
                                                F: 80-101                                                                                                                            

  MCH                              pg           M: 28.2-34.7\    29.9±2.0            30.2±1.9            P = 0.045\*     29.8±2.1            P = 0.932          29.6±2.1             P = 0.045\*
                                                F: 26.4-34.3                                                                                                                         

  MCHC                             \%           M: 31.8-36.4\    33.2±1.2            33.5±1.1            P = 0.105       32.8±1.2            P = 0.029\*        33.1±1.2             P = 0.982
                                                F: 31.3-36.1                                                                                                                         

  Platelet Count                   ×10^4^ /μL   14.0-37.9        25.6±5.5            25.8±5.1            P = 0.947       26.1±6.0            P = 0.696          26.9±4.9             P = 0.051

  Total Protein (TP)               g/dL         6.5-8.2          7.06±0.34           7.01±0.36           P = 0.879       7.01±0.39           P = 0.879          7.23±0.30            P \< 0.050\*

  A/G Ratio                        \-           1.30-2.00        1.70±0.23           1.74±0.21           P = 0.160       1.73±0.24           P = 0.361          1.75±0.24            P = 0.080

  Albumin (Alb)                    g/dL         3.7-5.5          4.42±0.29           4.44±0.32           P = 0.947       4.42±0.26           P = 1.000          4.58±0.28            P = 0.002\*\*

  Uric Acid (UA)                   mg/dL        M: 3.6-7.0\      5.13±1.33           5.05±1.35           P = 0.835       4.95±1.30           P = 0.312          5.24±1.29            P = 0.657
                                                F: 2.7-7.0                                                                                                                           

  Urea Nitrogen (UN)               mg/dL        8.0-20.0         11.8±3.2            12.2±3.1            P = 0.709       12.8±3.3            P = 0.100          12.0±3.1             P = 0.952

  LDL Cholesterol                  mg/dL        70-139           112±36              114±39              P = 0.881       114±37              P = 0.930          121±39               P = 0.011\*

  Creatinine (CREA)                mg/dL        M: 0.65-1.09\    0.725±0.154         0.690±0.145         P = 0.028\*     0.724±0.156         P = 1.000          0.759±0.153          P = 0.035\*
                                                F: 0.46-0.82                                                                                                                         

  Sodium (Na)                      mEq/L        135-145          141±2               141±1               P = 0.967       141±1               P = 0.555          141±2                P = 0.640

  Chlorine (Cl)                    mEq/L        98-108           104±1               105±2               P = 0.007\*\*   104±2               P = 0.906          103±2                P = 0.716

  Total Cholesterol                mg/dL        150-219          192±36              198±41              P = 0.236       202±40              P = 0.014\*        209±38               P \< 0.001\*\*\*

  Triglyceride (TG)                mg/dL        50-149           85.0±57.5           84.0±43.3           P = 0.997       87.9±51.9           P = 0.936          81.9±39.0            P = 0.921

  HDL Cholesterol                  mg/dL        M: 40-80\        65.2±16.0           67.4±21.5           P = 0.324       67.2±19.3           P = 0.412          72.0±21.4            P \< 0.001\*\*\*
                                                F: 40-90                                                                                                                             

  Total Bilirubin                  mg/dL        0.3-1.2          0.796±0.336         0.736±0.258         P = 0.364       0.744±0.289         P = 0.478          0.752±0.318          P = 0.605

  AST (GOT)                        U/L          10-40            20.8±4.8            20.7±4.0            P = 0.999       21.4±5.0            P = 0.911          22.8±8.0             P = 0.111

  ALT (GPT)                        U/L          5-45             19.8±12.0           19.9±10.0           P = 1.000       21.7 ±11.9          P = 0.301          22.8±13.9            P = 0.054

  ALP                              U/L          104-338          184±54              181±42              P = 0.911       189±51              P = 0.588          193±52               P = 0.188

  **Item**                         **Unit**     **Normal**       **Before Admin.**   **4 Weeks after**   **Overtime**\   **8 Weeks after**   **Overtime**\      **12 Weeks after**   **Overtime**\
                                                                                                         **P-Value**                         **p-Value**                             **p-Value**

  γ-GT (γ-GTP)                     U/L          M: [≤]{.ul}79\   23.6±13.8           25.0±16.5           P = 0.847       28.8±23.5           P = 0.031\*        30.8±21.5            P = 0.002\*\*
                                                F: [≤]{.ul}48                                                                                                                        

  LD (LDH)                         U/L          120-245          172±19              172±23              P = 0.987       170±24              P = 0.729          176±23               P = 0.356

  Blood Sugar (fasting)            mg/dL        70-109           91.0±7.2            92.4±6.1            P = 0.607       96.1±8.8            P \< 0.001\*\*\*   91.1±7.5             P = 1.000

  Protein Qualitative-Urine        \-           \-               0.440 ±1.003        0.080±0.400         P = 0.034       0.240±0.723         P = 0.129          0.520±0.963          P = 0.608

  Sugar Qualitative-Urine          \-           \-               0.000±0.000         0.000±0.000         P = 1.000       0.040±0.200         P = 0.317          0.000±0.000          P = 1.000

  Urobilinogen Qualitative-Urine   \-           \-               1.000±0.000         1.000±0.000         P = 1.000       1.000±0.000         P=1.000            1.040±0.200          P = 0.317

  Bilirubin Qualitative-Urine      \-           \-               0.000±0.000         0.000±0.000         P = 1.000       0.000±0.000         P=1.000            0.000±0.000          P = 1.000

  Ketone Body Qualitative-Urine    \-           \-               0.000±0.000         0.000±0.000         P = 1.000       0.080±0.400         P=0.317            0.120±0.600          P = 0.317

  Occult Blood-Urine               \-           \-               0.280±0.891         0.320±0.945         P = 0.317       0.320±0.945         P=0.317            0.560±1.083          P = 0.020

  Specific Gravity-Urine           \-           \-               1.018±0.008         1.013±0.008         P = 0.008\*\*   1.017±0.008         P=0.972            1.017±0.010          P = 0.978

  Reaction pH-Urine                \-           \-               6.060±0.712         6.080±0.640         P = 0.998       6.160±0.688         P = 0.854          5.940±0.565          P = 0.777
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*:P \< 0.05; \*\*:P \< 0.01; \*\*\*:P \< 0.001; mean ± standard deviations; n = 25

###### 

Blood pressures (seated position) and pulse rates (seated position).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Item**                   **Unit**    **Before**\          **4 Weeks after Administration**   **Passage p-value from Start**   **8 Weeks after Administration**   **Passage p-value from Start**   **12 Weeks after Administration**   **Passage**\
                                         **Administration**                                                                                                                                                                               **p-value from Start**
  -------------------------- ----------- -------------------- ---------------------------------- -------------------------------- ---------------------------------- -------------------------------- ----------------------------------- ------------------------
  Systolic Blood Pressure    mmHg        125 ± 11             116 ± 9                            p \< 0.001\*\*\*                 114 ± 11                           p \< 0.001\*\*\*                 119 ± 11                            p = 0.002\*\*

  Diastolic Blood Pressure   mmHg        76.5 ± 8.0           70.6 ± 8.8                         p = 0.001\*\*                    70.3 ± 10.2                        p \< 0.001\*\*\*                 72.0 ± 10.8                         p = 0.019\*

  Pulse Rate                 beats/min   72.5 ± 11.9          73.1 ± 13.3                        p = 0.975                        73.1 ± 13.4                        p = 0.975                        75.3 ± 10.7                         p = 0.271
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001; mean ± standard deviation; n = 25
